Skip to main
TECH

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 0%
Hold 82%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is a well-established life sciences manufacturer with a strong foothold in the pharma, biotech, academic, and diagnostic markets. With a diverse product portfolio, strong sales in the US and international markets, and a strategic focus on sustainability and human capital management, the company is well-positioned for long-term growth potential. Additionally, the pending acquisition of Wilson Wolf could further boost sales and solidify Bio-Techne's position as a leader in the cell therapy market. While there are potential risks to consider, such as potential market downturns and competition from larger companies, we believe that Bio-Techne's strong financials and strategic initiatives make it a solid investment for the future.

Bears say

Bio-Techne is facing potential downsides and concerns including acquisition risks, competition and share loss, reliance on cell therapy development, and potential decrease in demand for wet lab work due to advancements in dry lab technology. Though the company is aggressively improving business operations and has the potential for long-term growth through the Wilson Wolf acquisition, the current proposed takeout price by Merck KGaA at $73 is likely to close. However, the lack of science-based emissions targets raises concerns about the company's sustainability efforts.

Bio-Techne (TECH) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 0% recommend Buy, 82% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Hold based on their latest research and market trends.

According to 11 analysts, Bio-Techne (TECH) has a Hold consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.